Yale University School of Medicine
New Haven, Connecticut, United States
Research institution in New Haven, Connecticut
333 Cedar St, New Haven, CT 06510
About Yale University School of Medicine
The Yale School of Medicine is the graduate medical school at Yale University in New Haven, Connecticut. It was founded in 1810 as the Medical Institution of Yale College and formally opened in 1813. The primary teaching hospital for the school is Yale New Haven Hospital.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Yale University
169
Bristol-Myers Squibb
45
National Institute of Allergy and Infectious Diseases (NIAID)
22
Eli Lilly and Company
20
Hoffmann-La Roche
17
Pfizer
17
Gilead Sciences
14
Boehringer Ingelheim
9
Boston Scientific Corporation
9
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
9
Novartis Pharmaceuticals
8
Clinical Trials at Yale University School of Medicine
During the past decade, Yale University School of Medicine conducted 353 clinical trials. In the 10-year time frame, 353 clinical trials started and 220 clinical trials were completed, i.e. on
average, 62.3% percent of trials that started reached the finish line to date. In the past 5 years, 118 clinical trials started and 106 clinical trials were completed. i.e. 89.8%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children
1996-09-01
Completed
819
A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection
1996-09-01
Completed
400
Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)
1998-07-01
Completed
24
A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
2001-11-01
Completed
690
A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease
1998-11-01
Completed
390
A Study on the Effect of High-Calorie Infant Formula on Growth and Nutrition in HIV-Infected Infants
2005-09-01
Completed
2,400
Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children
2000-10-01
Completed
24
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Yale University School of Medicine" #1 sponsor was "Yale University" with 169 trials, followed by "Bristol-Myers Squibb" with 45 trials
sponsored, "National Institute of Allergy and Infectious Diseases (NIAID)" with 22 trials sponsored, "Eli Lilly and Company" with 20 trials sponsored and "Hoffmann-La Roche"
with 20 trials sponsored. Other sponsors include 439 different institutions and
companies that sponsored additional 250 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Yale University School of Medicine"
#1 collaborator was "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" with 32 trials as a collaborator, "National Institute on Drug Abuse (NIDA)" with 25 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 17 trials as a collaborator, "Yale University" with 17 trials as a collaborator and "National Institute on Aging (NIA)" with 16 trials as a collaborator. Other collaborators include 429 different institutions and companies that were
collaborators in the rest 241 trials.
Clinical Trials Conditions at Yale University School of Medicine
According to Clinical.Site data, the most researched conditions in "Yale University School of Medicine" are
"HIV Infections" (26 trials), "Alzheimer's Disease" (22 trials), "Type 1 Diabetes" (21 trials), "Obesity" (15 trials) and "Alzheimer Disease" (14 trials). Many other conditions were trialed in "Yale University School of Medicine" in a lesser frequency.
Clinical Trials Intervention Types at Yale University School of Medicine
Most popular intervention types in "Yale University School of Medicine" are "Drug" (454 trials), "Other" (98 trials), "Device" (85 trials), "Biological" (59 trials) and "Behavioral" (52 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (153 trials), "placebo" (17 trials), "Nivolumab" (10 trials), "Atezolizumab" (9 trials) and "Ipilimumab" (8 trials). Other intervention names were less common.
Clinical Trials Genders at Yale University School of Medicine
The vast majority of trials in "Yale University School of Medicine" are
655 trials for "All" genders, 47 trials for "Female" genders and 15 trials for "Male" genders.
Clinical Trials Status at Yale University School of Medicine
Currently, there are 188 active trials in "Yale University School of Medicine".
3 are not yet recruiting,
93 are recruiting,
86 are Active, not recruiting,
and 6 are Enrolling by invitation.
In total, there were 425 completed trials in Yale University School of Medicine,
4 suspended trials,
and 85 terminated clinical trials to date.
Out of the total trials that were conducted in Yale University School of Medicine, 89 "Phase 1"
clinical trials were conducted, 224 "Phase 2" clinical
trials and 197 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 27 trials, and there were
also 138 trials that are defined as “Not Applicable".